Voices

A Brilliant Overview of Science Driving Our Field Forward by Teresa Lopez Fernandez

Teresa Lopez Fernandez/doctoralia.es

Aug 31, 2025, 19:31

A Brilliant Overview of Science Driving Our Field Forward by Teresa Lopez Fernandez

Hasnaa Belghiti, Fellow of ESC Member of board of ESC, shared a post on LinkedIn:

“At ESCCongress2025 in Madrid, Prof. Teresa Lopez Fernandez presented the Top Papers in Cardio-Oncology 2025 – a brilliant overview of science driving our field forward.

10. API-CAT trial
Reduced-dose apixaban kept efficacy & lowered bleeding.
Key message: Extended anticoagulation can be safer.
NEJM 2025;392:1363–1373

9. VTE recurrence & bleeding predictors
Clinical/biological predictors guide recurrence vs bleeding.
Key message: No “one size fits all” – anticoagulation must be tailored.
EHJ 2025; eha453

8. SGLT2i in cancer survivors
↓ HF hospitalisations & ↓ AF; ongoing RCTs (EMPACON, DAPA-CARDIO-ONC, PREVENT-HF).
Key message: SGLT2i may protect beyond diabetes & HF.
EJPC 2025; zwa026

7. SUCCOUR-MRI
GLS decline precedes LVEF drop, enabling earlier cardioprotection.
Key message: Strain is the most sensitive marker for early CTRCD.
EHJ 2025;46:4325–4437

6. ICI-myocarditis risk score
Validated score predicts 30-day outcomes (4% → 81%).
Key message: Simple tool to stratify risk & guide care.
EHJ 2025; eha315

5. CTCAE v6.0
New definitions of CV toxicities, grades 1–5.
Key message: International harmonisation of endpoints.
MedDRA 28.0, 2025

4. HFA-ICOS & CARDIOTOX registry
Validation in anthracycline-treated patients.
Key message: HFA-ICOS is reliable for baseline risk.
EHJ 2025;46:273–284

3. BACCARAT study
Radiotherapy ↑ coronary inflammation (FAI); tumors trigger it too.
Key message: Inflammation amplifies CAD in cancer, worsened by RT.
EHJ 2025;46(29):2924–2927

2. Empagliflozin & anthracyclines
Dose-dependent cardioprotection against anthracycline toxicity.

Key message: SGLT2i could become preventive therapy.
JACC CardioOncol 2025;7:171–184

1. IL-1α & anthracycline cardiotoxicity

IL-1α identified as key mediator in CTRCD.

Key message: Blocking IL-1α opens a new therapeutic avenue.
EHJ 2024;45:2235–2250

Take-home:

Inflammation is central (IL-1α, tumor & RT).
Risk scores (HFA-ICOS, ICI myocarditis) are now clinically relevant.
New therapies (SGLT2i RCTs, tailored anticoagulation, anti-IL-1) pave the way for precision cardio-oncology.

Congratulations to Teresa Lopez Fernandez for this outstanding synthesis!”

Hasnaa Belghiti